Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Главные авторы: Xiaomin Wan (Автор), Xiaohui Zeng (Автор), Liubao Peng (Автор), Ye Peng (Автор), Qiao Liu (Автор), Lidan Yi (Автор), Xia Luo (Автор), Qijian Deng (Автор), Chongqing Tan (Автор)
• Формат: ‌
• Опубликовано: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Предметы: article
• Online-ссылка: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...